Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

AbbVie to buy cancer drugmaker Pharmacyclics for $21bn US-based biopharmaceutical firm AbbVie has entered into an agreement to acquire Pharmacyclics, including its cancer drug Imbruvica (ibrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, designed to treat hematologic malignancies, for about $21bn. Production & Manufacturing > Manufacturing > News
Bayer's BLA for Kovaltry gets FDA acceptance to treat hemophilia A By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted Bayer HealthCare's biologics license application (BLA) for BAY 81-8973 (Kovaltry), a recombinant Factor VIII compound, for the treatment of hemophilia A in children and adults.
News European Commission approves new indication of Pfizer's Prevenar 13 By PBR Staff Writer
The European Commission has approved an expanded indication for the use Pfizer's Prevenar 13 (pneumococcal polysaccharide conjugate vaccine) to prevent pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.
News Eisai, Merck to develop new combination regimens for multiple cancer types By PBR Staff Writer
Japanese pharmaceutical firm Eisai has entered into clinical trial collaboration with Merck to discover new combination regimens of anti-PD-1 therapy with multi-targeting RTK inhibitor and microtubule dynamics inhibitor to treat multiple types of cancer.
News
Bristol-Myers enters into $975m deal for Bavarian Nordic's Prostvac to treat prostate cancer By PBR Staff Writer
Bristol-Myers Squibb has entered into a $975m option and licensing deal with Danish biotech firm Bavarian Nordic for its prostate-cancer vaccine candidate Prostvac.
News AbbVie to buy cancer drugmaker Pharmacyclics for $21bn By PBR Staff Writer
US-based biopharmaceutical firm AbbVie has entered into an agreement to acquire Pharmacyclics, including its cancer drug Imbruvica (ibrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, designed to treat hematologic malignancies, for about $21bn.
News BMS' cancer drug Opdivo gets FDA approval to treat NSCLC By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted approval for Bristol-Myers Squibb's (BMS) Opdivo (nivolumab) injection, for intravenous use, to treat patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
News

Latest News and Insight by Sector

Production & Manufacturing

AbbVie to buy cancer drugmaker Pharmacyclics for $21bn
By PBR Staff Writer
US-based biopharmaceutical firm AbbVie has entered into an agreement to acquire Pharmacyclics, including its cancer drug Imbruvica (ibrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, designed to treat hematologic malignancies, for about $21bn.
News
Actavis' Xydalba gets approval in Europe to treat ABSSSI
By PBR Staff Writer
Irish pharmaceutical firm Actavis has received marketing approval from the European Commission for Xydalba (dalbavancin), a once-weekly IV antibiotic, to treat acute bacterial skin and skin structure infections (ABSSSI) in adults.
News

Drug Research

European Commission approves new indication of Pfizer's Prevenar 13
By PBR Staff Writer
The European Commission has approved an expanded indication for the use Pfizer's Prevenar 13 (pneumococcal polysaccharide conjugate vaccine) to prevent pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.
News
Eisai, Merck to develop new combination regimens for multiple cancer types
By PBR Staff Writer
Japanese pharmaceutical firm Eisai has entered into clinical trial collaboration with Merck to discover new combination regimens of anti-PD-1 therapy with multi-targeting RTK inhibitor and microtubule dynamics inhibitor to treat multiple types of cancer.
News

Inward Investment

PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
News
Merck in talks to acquire Cubist Pharmaceuticals for nearly $8bn
By PBR Staff Writer
New Jersey-based drug giant Merck & Co is, reportedly, in talks over a potential acquisition of antibiotics maker Cubist Pharmaceuticals for more than $8bn.
News

Packaging

MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
News
Bosch expands CPS portfolio for serialization of pharmaceutical packaging
Bosch Packaging Technology, a leading supplier of process and packaging technology, has expanded its portfolio for the serialization of pharmaceutical packaging. In the fight against counterfeit drugs, many countries are about to implement legislation changes for a stricter labelling of pharmaceuticals. Consequently, drug manufacturers require safer and more flexible solutions.
News

Contract Research & Services

Bristol-Myers enters into $975m deal for Bavarian Nordic's Prostvac to treat prostate cancer
By PBR Staff Writer
Bristol-Myers Squibb has entered into a $975m option and licensing deal with Danish biotech firm Bavarian Nordic for its prostate-cancer vaccine candidate Prostvac.
News
Islet, Brighthaven Ventures ink license deal for Phase II SGLT2 inhibitor remogliflozin
By PBR Staff Writer
Islet Sciences has entered into a license agreement with Brighthaven Ventures (BHV) for exclusive rights to develop and commercialize SGLT2 inhibitor remogliflozin, which is currently Phase IIb development for patients with type 2 diabetes and non-alcoholic steatohepatitis (NASH).
News

Automation

Celgene's lung cancer drug Abraxane gets approval in Europe
By PBR Staff Writer
The European Commission (EC) has granted approval for Celgene International's Abraxane in combination with carboplatin for the first-line treatment of non-small cell lung cancer (NSCLC) in adult patients.
News
Lupin enters into clinical research partnership with Acceliant
By PBR Staff Writer
India-based drugmaker Lupin has entered into partnership with Acceliant, a provider of advanced clinical trial data management solutions, to use its clinical trial platform for drug research programs.
News

Regulatory Affairs

Bayer's BLA for Kovaltry gets FDA acceptance to treat hemophilia A
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted Bayer HealthCare's biologics license application (BLA) for BAY 81-8973 (Kovaltry), a recombinant Factor VIII compound, for the treatment of hemophilia A in children and adults.
News
EMA committee issues positive opinion for Novartis' lung cancer drug Zykadia
By PBR Staff Writer
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinion recommending approval for Novartis' Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
News

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Reports Buy online from $250



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery